Published in Healthcare Mergers, Acquisitions and Ventures Week, September 26th, 2009
James C. Mullen, Biogen Idec's President and Chief Executive Officer, stated, "We continue to believe that Biogen Idec's $14.50 per share, all-cash offer represents an extremely attractive opportunity for Facet's shareholders to realize today the future value of their company. The price we are offering ascribes meaningful and appropriate value to the company's clinical programs while taking into account Facet's significant building lease and other obligations, and recently announced collaboration agreement with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.